Skip to main content
BALAXI PHARMACEUTICALS LIMITED logo

BALAXI PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · BALAXI ISIN · INE618N01022 LEI · 894500VRENAYIIWHHQ13 National Stock Exchange of India Wholesale and retail trade
Open in API
Filings indexed 615 across all filing types
Latest filing 2024-11-05 Interim / Quarterly Rep…
Country IN India
Listing National Stock Exchange of India BALAXI

About BALAXI PHARMACEUTICALS LIMITED

https://www.balaxipharma.in/

Balaxi Pharmaceuticals Limited is a specialty pharmaceutical company that operates an asset-light business model focused on sourcing, branding, and distributing generic formulations in frontier markets. The company primarily serves emerging economies across Africa and Latin America, including Angola, Guatemala, and the Dominican Republic. Its product portfolio encompasses a wide range of therapeutic segments such as anti-infectives, analgesics, and antimalarials. Balaxi manages an integrated supply chain, leveraging its regulatory expertise to register and market high-quality pharmaceutical products. By maintaining a robust distribution network and localized presence, the company ensures the availability of essential medicines in underserved regions while optimizing operational efficiency through its specialized procurement and logistics framework.

Recent filings

Filing Released Lang Actions
Appointment
Interim / Quarterly Report Classification · 95% confidence The document is dated November 5, 2024, and is addressed to the National Stock Exchange of India. It announces the outcome of a Board Meeting held on the same date. The key points include approval of standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2024, accompanied by a Limited Review Report from statutory auditors. Additionally, it announces the resignation and appointment of the Company Secretary and Compliance Officer. The document contains detailed financial data for the quarter and half year, including income, expenses, and profit figures, indicating substantive financial information rather than a mere announcement. The presence of unaudited financial results for a quarter and half year period aligns with the definition of an Interim / Quarterly Report (IR). The document is not a full annual report, nor is it just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-11-05 English
Resignation
Interim / Quarterly Report Classification · 95% confidence The document is dated November 5, 2024, and is addressed to the National Stock Exchange of India. It announces the outcome of a Board Meeting held on the same date. The key points include approval of standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2024, accompanied by a Limited Review Report from statutory auditors. The document also includes management changes (resignation and appointment of Company Secretary and Compliance Officer). The financial results are unaudited and for a quarter and half year period, which fits the definition of an Interim / Quarterly Report (IR). The presence of actual financial data and review by auditors confirms this classification. The management changes are secondary and do not override the primary content of financial results. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR).
2024-11-05 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is dated November 5, 2024, and is addressed to the National Stock Exchange of India. It announces the outcome of a Board Meeting held on the same date. The key points include approval of standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2024, accompanied by a Limited Review Report from statutory auditors. Additionally, it announces the resignation and appointment of the Company Secretary and Compliance Officer. The document contains detailed financial data for the quarter and half year, including income, expenses, and profit figures, indicating substantive financial information rather than a mere announcement. The presence of unaudited financial results and limited review report aligns with the characteristics of an Interim / Quarterly Report. The document is not a full annual report, nor is it a simple announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-11-05 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is dated November 5, 2024, and reports the outcome of a Board Meeting of Balaxi Pharmaceuticals Limited. It includes approval of standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2024, accompanied by a Limited Review Report from statutory auditors. The document also announces resignation and appointment of the Company Secretary and Compliance Officer. The financial results are unaudited and pertain to a quarterly/half-year period, indicating an interim/quarterly report. The presence of detailed financial data and analysis confirms it is a substantive financial report, not just an announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-11-05 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2024-10-29 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the stock exchange's listing department, notifying about an upcoming Board Meeting scheduled to consider and approve unaudited financial results for the quarter and half year ended September 30, 2024. It references regulatory compliance under SEBI Listing Obligations and Disclosure Requirements and insider trading regulations. The document does not contain any financial data or results itself, but rather serves as an announcement of the Board Meeting where such results will be approved. The document length is short (1790 characters) and it is clearly an intimation or notice rather than a report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-10-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.